Immatics (IMTX) EPS (Weighted Average and Diluted) (2021 - 2024)
Immatics recorded quarterly EPS (Weighted Average and Diluted) of $0.45 in Q4 2024, up 610.84% quarter-over-quarter from -$0.09 in Q3 2024, and up 251.87% year-over-year from $0.13 in Q1 2024.
Immatics' EPS (Weighted Average and Diluted) history runs 4 years deep, the most recent figure standing at $0.45 for Q4 2024.
- In Q4 2024, EPS (Weighted Average and Diluted) rose 251.87% year-over-year to $0.45; the TTM figure through Dec 2024 stood at $0.15 (up 149.16% YoY), while the FY2025 annual figure was -$1.82, down 1315.88% from the prior year.
- EPS (Weighted Average and Diluted) came in at $0.45 for Q4 2024 at Immatics, up from -$0.09 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $63453.3 in Q1 2022 to a low of -$42.43 in Q2 2023.
- A 4-year average of $5284.1 and a median of -$0.18 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 23462.33% in 2023 and surged 251.87% in 2024, its largest moves.
- Immatics' EPS (Weighted Average and Diluted) stood at -$0.43 in 2021, then soared by 118.89% to $0.08 in 2022, then slumped by 461.71% to -$0.3 in 2023, then soared by 251.87% to $0.45 in 2024.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $0.45, -$0.09, and -$0.18 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.45 |
| Sep 30, 2024 | -0.09 |
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | -0.03 |
| Dec 31, 2023 | -0.30 |
| Sep 30, 2023 | -0.32 |
| Jun 30, 2023 | -42.43 |
| Dec 31, 2022 | 0.08 |
| Sep 30, 2022 | -0.30 |
| Jun 30, 2022 | -0.18 |
| Mar 31, 2022 | 63,453.33 |
| Sep 30, 2021 | -0.43 |